Ruby Gomez, APRN
Family · McAllen, TXNPI 1821595265
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.4% of the total across 256 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,500, 2.8 times the $1,629 reported in 2021. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 256 payments — averaging $51.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Johnson & Johnson$1K
- Novo Nordisk$1K
- E.r. Squibb & Sons, L.L.C.$926
- Amgen$820
- Lilly USA, LLC$794
- plus $7K from 37 others
What the payments were for
- Speaking & faculty fees$1021%
- Food & beverage$12,27793%
- Education$7656%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,144 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 18 | $240 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $171 |
| Fluconazole | 12 | $118 |
| Mupirocin | 11 | $72 |
Paid to pharmacies, not to this prescriber.
Other family in McAllen
- April LopezMcAllen$417K
- David WeirDallas$959K
- Robin BeachHouston$428K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.